The Fast and the Furious: Chasing a Clinical Niche for COVID-19 Convalescent Plasma.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35969864.
- Also identified by DOI 10.7326/M22-2329 and PMC identifier 9384270.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The Association for the Advancement of Blood and Biotherapies reported a thorough analysis of existing data and guidelines for the use of COVID-19 convalescent plasma (CCP) for treatment and prophylaxis of COVID-19. The editorialists discuss the recommendations, how they compare with recommendations from other entities, and the lessons the experience with CCP provides for the use of passive immunotherapy for future emerging infectious diseases.
Medical subject headings
- COVID-19